RECURRENT MYELODYSPLASTIC SYNDROME
Clinical trials for RECURRENT MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for RECURRENT MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Two-Drug attack on tough blood cancers
Disease control OngoingThis study is testing whether adding a new oral drug called seclidemstat to a standard chemotherapy (azacitidine) is safe and effective for patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The trial will first find the best dose and then se…
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 04, 2026 05:06 UTC
-
New hope for kids with tough leukemia: early trial tests drug to boost chemo
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug called uproleselan when given with two standard chemotherapy drugs (fludarabine and cytarabine). It is for children and teenagers (ages 1-17) whose acute myeloid leukemia, myelodysplastic syndrome, or mixed …
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 04, 2026 05:06 UTC
-
Scientists test Immune-Boosting combo against tough blood cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a two-drug combination for patients with advanced myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The trial combines a chemotherapy drug (decitabine…
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New hope for tough blood cancers: testing a Triple-Drug attack
Disease control OngoingThis study is testing a new combination of three drugs—navitoclax, venetoclax, and decitabine—for patients with a high-risk type of blood and bone marrow cancer called myelodysplastic syndrome (MDS) that has come back or hasn't responded to standard treatments. The main goals are…
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New hope for transplant patients as cancer returns? early trial tests Immune-Boosting shot
Disease control TerminatedThis early-stage study is testing a new drug called DR-18 for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose cancer has come back or persisted after a stem cell transplant. The main goals are to find a safe dose and see what side effects it cau…
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New pill trial targets genetic flaw in tough blood cancers
Disease control OngoingThis study is testing if a pill called olaparib can help control advanced blood cancers (acute myeloid leukemia or myelodysplastic syndrome) that have come back or haven't responded to standard treatments. It is for adults whose cancer has a specific genetic change called an IDH …
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug combo trial offers hope for Tough-to-Treat blood disorder
Disease control OngoingThis study is testing whether combining two immunotherapy drugs (nivolumab and ipilimumab) with a chemotherapy drug (azacitidine) is safe and effective for treating myelodysplastic syndromes (MDS), a type of blood and bone marrow cancer. It is for 99 patients, including those new…
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New transplant strategy aims to tame blood cancers and reduce rejection
Disease control OngoingThis study is testing a modified stem cell transplant procedure for patients with high-risk blood cancers. The goal is to see if using specific chemotherapy drugs in a timed sequence before and after the transplant can better control the cancer while reducing harmful immune react…
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New hope for tough blood cancers: testing a Two-Drug attack
Disease control OngoingThis study is testing a new combination of two drugs, venetoclax and azacitidine, for patients with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has come back or stopped responding to standard treatment. The first part of the study aims …
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New hope for tough leukemia: Triple-Drug attack enters early testing
Disease control TerminatedThis early-stage study is testing the safety and best dose of a new three-drug combination for adults with acute myeloid leukemia (AML) or related blood cancers that have come back or not responded to prior treatments. The goal is to see if adding the drug regorafenib to two exis…
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC